Legal & General Group PLC Affimed N.V. Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $4,890 - $8,283	2,495 Added 16.64%	17,491 $36,000
Q2 2022 Aug 22, 2022	BUY	$2.27 - $4.86 $6,104 - $13,068	2,689 Added 21.85%	14,996 $41,000
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $206 - $316	-56 Reduced 0.45%	12,307 $54,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $1,412 - $1,859	263 Added 2.17%	12,363 $68,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $1,157 - $1,569	-209 Reduced 1.7%	12,100 $75,000
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $159,073 - $263,465	-31,069 Reduced 71.62%	12,309 $98,000
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $105,749 - $235,258	33,465 Added 337.59%	43,378 $253,000
Q3 2020 Nov 13, 2020	SELL	$3.26 - $4.73 $8,166 - $11,848	-2,505 Reduced 20.17%	9,913 $34,000
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $1,270 - $3,722	804 Added 6.92%	12,418 $57,000
Q1 2020 May 14, 2020	SELL	$1.44 - $3.02 $4,983 - $10,452	-3,461 Reduced 22.96%	11,614 $18,000
Q4 2019 Feb 13, 2020	BUY	$2.25 - $3.07 $11,378 - $15,524	5,057 Added 50.48%	15,075 $41,000
Q2 2019 Aug 14, 2019	BUY	$2.6 - $4.21 $26,046 - $42,175	10,018 New	10,018 $22,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $154M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.